The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Spinal Muscular Atrophy (SMA) Treatment Market Research Report 2025
Synopsis
Spinal muscular atrophy (SMA) refers to a group of inherited diseases that affects the functioning of muscles because of deterioration.
The global Spinal Muscular Atrophy (SMA) Treatment market was valued at US$ 915.4 million in 2023 and is anticipated to reach US$ 1546.6 million by 2030, witnessing a CAGR of 7.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Treatment.
Report Scope
The Spinal Muscular Atrophy (SMA) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal Muscular Atrophy (SMA) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy (SMA) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Isis Pharmaceuticals
Biogen Idec
Boehringer Ingelheim
F. Hoffmann-La Roche
Regeneron Pharmaceuticals
Segment by Type
Type I Spinal Muscular Atrophy (SMA)
Type II Spinal Muscular Atrophy (SMA)
Type III Spinal Muscular Atrophy (SMA)
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Spinal muscular atrophy (SMA) refers to a group of inherited diseases that affects the functioning of muscles because of deterioration.
The global Spinal Muscular Atrophy (SMA) Treatment market was valued at US$ 915.4 million in 2023 and is anticipated to reach US$ 1546.6 million by 2030, witnessing a CAGR of 7.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Treatment.
Report Scope
The Spinal Muscular Atrophy (SMA) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal Muscular Atrophy (SMA) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy (SMA) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Isis Pharmaceuticals
Biogen Idec
Boehringer Ingelheim
F. Hoffmann-La Roche
Regeneron Pharmaceuticals
Segment by Type
Type I Spinal Muscular Atrophy (SMA)
Type II Spinal Muscular Atrophy (SMA)
Type III Spinal Muscular Atrophy (SMA)
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Type I Spinal Muscular Atrophy (SMA)
1.2.3 Type II Spinal Muscular Atrophy (SMA)
1.2.4 Type III Spinal Muscular Atrophy (SMA)
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Perspective (2019-2030)
2.2 Spinal Muscular Atrophy (SMA) Treatment Growth Trends by Region
2.2.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Spinal Muscular Atrophy (SMA) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Spinal Muscular Atrophy (SMA) Treatment Market Dynamics
2.3.1 Spinal Muscular Atrophy (SMA) Treatment Industry Trends
2.3.2 Spinal Muscular Atrophy (SMA) Treatment Market Drivers
2.3.3 Spinal Muscular Atrophy (SMA) Treatment Market Challenges
2.3.4 Spinal Muscular Atrophy (SMA) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Revenue
3.1.1 Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Revenue (2019-2024)
3.1.2 Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Treatment Revenue
3.4 Global Spinal Muscular Atrophy (SMA) Treatment Market Concentration Ratio
3.4.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Treatment Revenue in 2023
3.5 Spinal Muscular Atrophy (SMA) Treatment Key Players Head office and Area Served
3.6 Key Players Spinal Muscular Atrophy (SMA) Treatment Product Solution and Service
3.7 Date of Enter into Spinal Muscular Atrophy (SMA) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Spinal Muscular Atrophy (SMA) Treatment Breakdown Data by Type
4.1 Global Spinal Muscular Atrophy (SMA) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Type (2025-2030)
5 Spinal Muscular Atrophy (SMA) Treatment Breakdown Data by Application
5.1 Global Spinal Muscular Atrophy (SMA) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Spinal Muscular Atrophy (SMA) Treatment Market Size (2019-2030)
6.2 North America Spinal Muscular Atrophy (SMA) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024)
6.4 North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size (2019-2030)
7.2 Europe Spinal Muscular Atrophy (SMA) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024)
7.4 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size (2019-2030)
9.2 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024)
9.4 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Spinal Muscular Atrophy (SMA) Treatment Introduction
11.1.4 Pfizer Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Isis Pharmaceuticals
11.2.1 Isis Pharmaceuticals Company Detail
11.2.2 Isis Pharmaceuticals Business Overview
11.2.3 Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Introduction
11.2.4 Isis Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
11.2.5 Isis Pharmaceuticals Recent Development
11.3 Biogen Idec
11.3.1 Biogen Idec Company Detail
11.3.2 Biogen Idec Business Overview
11.3.3 Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Introduction
11.3.4 Biogen Idec Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
11.3.5 Biogen Idec Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
11.4.5 Boehringer Ingelheim Recent Development
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Detail
11.5.2 F. Hoffmann-La Roche Business Overview
11.5.3 F. Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Introduction
11.5.4 F. Hoffmann-La Roche Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
11.5.5 F. Hoffmann-La Roche Recent Development
11.6 Regeneron Pharmaceuticals
11.6.1 Regeneron Pharmaceuticals Company Detail
11.6.2 Regeneron Pharmaceuticals Business Overview
11.6.3 Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Introduction
11.6.4 Regeneron Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
11.6.5 Regeneron Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Type I Spinal Muscular Atrophy (SMA)
Table 3. Key Players of Type II Spinal Muscular Atrophy (SMA)
Table 4. Key Players of Type III Spinal Muscular Atrophy (SMA)
Table 5. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Region (2019-2024)
Table 9. Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Region (2025-2030)
Table 11. Spinal Muscular Atrophy (SMA) Treatment Market Trends
Table 12. Spinal Muscular Atrophy (SMA) Treatment Market Drivers
Table 13. Spinal Muscular Atrophy (SMA) Treatment Market Challenges
Table 14. Spinal Muscular Atrophy (SMA) Treatment Market Restraints
Table 15. Global Spinal Muscular Atrophy (SMA) Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Players (2019-2024)
Table 17. Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Treatment as of 2023)
Table 18. Ranking of Global Top Spinal Muscular Atrophy (SMA) Treatment Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Spinal Muscular Atrophy (SMA) Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Spinal Muscular Atrophy (SMA) Treatment Product Solution and Service
Table 22. Date of Enter into Spinal Muscular Atrophy (SMA) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Application (2019-2024)
Table 30. Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Application (2025-2030)
Table 32. North America Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Spinal Muscular Atrophy (SMA) Treatment Product
Table 50. Pfizer Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Isis Pharmaceuticals Company Detail
Table 53. Isis Pharmaceuticals Business Overview
Table 54. Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Product
Table 55. Isis Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024) & (US$ Million)
Table 56. Isis Pharmaceuticals Recent Development
Table 57. Biogen Idec Company Detail
Table 58. Biogen Idec Business Overview
Table 59. Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Product
Table 60. Biogen Idec Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024) & (US$ Million)
Table 61. Biogen Idec Recent Development
Table 62. Boehringer Ingelheim Company Detail
Table 63. Boehringer Ingelheim Business Overview
Table 64. Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Product
Table 65. Boehringer Ingelheim Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024) & (US$ Million)
Table 66. Boehringer Ingelheim Recent Development
Table 67. F. Hoffmann-La Roche Company Detail
Table 68. F. Hoffmann-La Roche Business Overview
Table 69. F. Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Product
Table 70. F. Hoffmann-La Roche Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024) & (US$ Million)
Table 71. F. Hoffmann-La Roche Recent Development
Table 72. Regeneron Pharmaceuticals Company Detail
Table 73. Regeneron Pharmaceuticals Business Overview
Table 74. Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Product
Table 75. Regeneron Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024) & (US$ Million)
Table 76. Regeneron Pharmaceuticals Recent Development
Table 77. Research Programs/Design for This Report
Table 78. Key Data Information from Secondary Sources
Table 79. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Type: 2023 VS 2030
Figure 3. Type I Spinal Muscular Atrophy (SMA) Features
Figure 4. Type II Spinal Muscular Atrophy (SMA) Features
Figure 5. Type III Spinal Muscular Atrophy (SMA) Features
Figure 6. Global Spinal Muscular Atrophy (SMA) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Diagnostic Centers Case Studies
Figure 11. Others Case Studies
Figure 12. Spinal Muscular Atrophy (SMA) Treatment Report Years Considered
Figure 13. Global Spinal Muscular Atrophy (SMA) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Spinal Muscular Atrophy (SMA) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Region: 2023 VS 2030
Figure 16. Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Players in 2023
Figure 17. Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Treatment as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Treatment Revenue in 2023
Figure 19. North America Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Spinal Muscular Atrophy (SMA) Treatment Market Share by Country (2019-2030)
Figure 21. United States Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Spinal Muscular Atrophy (SMA) Treatment Market Share by Country (2019-2030)
Figure 25. Germany Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Spinal Muscular Atrophy (SMA) Treatment Market Share by Region (2019-2030)
Figure 33. China Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Spinal Muscular Atrophy (SMA) Treatment Market Share by Country (2019-2030)
Figure 41. Mexico Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Share by Country (2019-2030)
Figure 45. Turkey Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Spinal Muscular Atrophy (SMA) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
Figure 48. Isis Pharmaceuticals Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
Figure 49. Biogen Idec Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
Figure 50. Boehringer Ingelheim Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
Figure 51. F. Hoffmann-La Roche Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
Figure 52. Regeneron Pharmaceuticals Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Treatment Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
